Home/Filings/4/0000950170-25-011242
4//SEC Filing

STEPHENSON BRIAN C 4

Accession 0000950170-25-011242

CIK 0001743881other

Filed

Jan 29, 7:00 PM ET

Accepted

Jan 30, 6:31 PM ET

Size

8.7 KB

Accession

0000950170-25-011242

Insider Transaction Report

Form 4
Period: 2025-01-28
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-28$17.00/sh+68,000$1,156,000161,758 total
  • Sale

    Common Stock

    2025-01-28$36.29/sh68,000$2,467,76193,758 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-01-2868,000448,670 total
    Exercise: $17.00Exp: 2029-06-26Common Stock (68,000 underlying)
Footnotes (3)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
  • [F2]Represents the weighted average sale price of the shares sold from $35.75 to $36.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F3]The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.

Documents

1 file

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1
  • filerCIK 0001780030

Filing Metadata

Form type
4
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 6:31 PM ET
Size
8.7 KB